Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1/2 activation.

Tsubaki, Masanobu; Takeda, Tomoya; Matsumoto, Mikihiro; Kato, Natsuki; Asano, Ryo-Ta; Imano, Motohiro; Satou, Takao; Nishida, Shozo.

Afiliação

Tsubaki M; Division of Pharmacotherapy, Kindai University School of Pharmacy Kowakae, Higashi-Osaka, Japan.
Takeda T; Division of Pharmacotherapy, Kindai University School of Pharmacy Kowakae, Higashi-Osaka, Japan.
Matsumoto M; Division of Pharmacotherapy, Kindai University School of Pharmacy Kowakae, Higashi-Osaka, Japan.
Kato N; Division of Pharmacotherapy, Kindai University School of Pharmacy Kowakae, Higashi-Osaka, Japan.
Asano RT; Division of Pharmacotherapy, Kindai University School of Pharmacy Kowakae, Higashi-Osaka, Japan.
Imano M; Department of Surgery, School of Medicine, Kindai University Osakasayama, Osaka, Japan.
Satou T; Department of Pathology, School of Medicine, Kindai University Osakasayama, Osaka, Japan.
Nishida S; Division of Pharmacotherapy, Kindai University School of Pharmacy Kowakae, Higashi-Osaka, Japan.

Am J Cancer Res ; 8(7): 1239-1248, 2018.

Article em En | MEDLINE | ID: mdl-30094097